Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -114.06% is 54% below its 3-year average of -74.14%, near the low end of its 3-year range (-120.53%–-40.46%).
As of the fiscal period ended Tuesday, June 30, 2026. 38.33% below its 12-month average of -82.46%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2026 (2026-06-30): -114.06%.
RETURN ON EQUITY (ROE)
-114.06%
RETURN ON EQUITY (ROE) AVG TTM
-82.46%
RETURN ON EQUITY (ROE) AVG 3Y
-74.14%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-38.33%
CURRENT VS 3Y AVG
-53.86%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-37.66%
median of 436 covered companies
CURRENT VS SECTOR MEDIAN
-202.88%
vs the sector median at left
Citius Oncology, Inc.
Market Cap
$81.22M
Return on Equity (ROE)
-114.06%
TTM Avg
-82.46%
3Y Avg
-74.14%
5Y Avg
N/A
Market Cap
$79.46M
Return on Equity (ROE)
-1542.57%
TTM Avg
-254.55%
3Y Avg
-187.52%
5Y Avg
-143.69%
Market Cap
$83.49M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$83.96M
Return on Equity (ROE)
-50.80%
TTM Avg
-124.86%
3Y Avg
-88.30%
5Y Avg
-60.21%
Market Cap
$84.00M
Return on Equity (ROE)
-309.44%
TTM Avg
-515.53%
3Y Avg
-464.77%
5Y Avg
-329.14%
Market Cap
$84.70M
Return on Equity (ROE)
N/A
TTM Avg
1.45%
3Y Avg
25.22%
5Y Avg
-14.52%
Market Cap
$84.75M
Return on Equity (ROE)
-85.65%
TTM Avg
-57.41%
3Y Avg
-45.73%
5Y Avg
-8.61%
Market Cap
$86.69M
Return on Equity (ROE)
45.93%
TTM Avg
16.96%
3Y Avg
-19.36%
5Y Avg
-13.87%
Market Cap
$87.86M
Return on Equity (ROE)
-150.95%
TTM Avg
-77.89%
3Y Avg
-62.90%
5Y Avg
-47.80%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Citius Oncology, Inc. (CTOR) | $81.22M | -114.06% | -82.46% | -74.14% | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $79.46M | -1542.57% | -254.55% | -187.52% | -143.69% |
| Conexeu Sciences Inc. (CNXU)vs › | $83.49M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | -50.80% | -124.86% | -88.30% | -60.21% |
| Humacyte, Inc. (HUMA)vs › | $84.00M | -309.44% | -515.53% | -464.77% | -329.14% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | N/A | 1.45% | 25.22% | -14.52% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | -85.65% | -57.41% | -45.73% | -8.61% |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 45.93% | 16.96% | -19.36% | -13.87% |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | -150.95% | -77.89% | -62.90% | -47.80% |
| Hyperfine, Inc. (HYPR)vs › | $74.35M | -94.81% | -84.90% | -70.34% | -58.48% |
ROE
-114.1%
ROA
-41.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -114.06% |
| 2026-03-31 | -120.53% |
| 2025-12-31 | -40.46% |
| 2025-09-30 | -55.19% |
| 2025-06-30 | -82.04% |
| 2025-03-31 | -72.89% |
| 2024-12-31 | -55.90% |
| 2024-09-30 | -45.84% |
| 2024-06-30 | -114.64% |
| 2024-03-31 | -88.07% |
| 2023-12-31 | -68.52% |
| 2023-09-30 | -49.72% |
| 2023-06-30 | -55.90% |
